VIDEO: AVD-104 shows stability, GA lesion size reduction in phase 2/3 trial
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Mohamed Genead, MD, CEO of Aviceda Therapeutics, discusses a trial investigating AVD-104 for geographic atrophy secondary to age-related macular degeneration.
The first in-human phase 2/3 SIGLEC trial found that AVD-104 (glycan-coated nanoparticle) was well-tolerated and demonstrated no drug-related serious adverse events after a single injection at baseline. The drug also demonstrated stability and regression in GA lesion size, Genead said.
The FDA cleared an investigational new drug application for AVD-104 for GA treatment earlier this year.
Collapse
Genead M. Aviceda Therapeutics. Presented at: Eyecelerator@AAO; Nov. 2, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts